AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03703388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arctigenin
Description: Arctigenin capsule
Study NCT03277534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: sensory electrical stimulation was applied prior to upper limb functional training
Study NCT03277534 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electrical stimulation
Description: electrodes were placed on the same location as the Electrical stimulation condition, but no electric current was applied
Study NCT00265200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 3.0-4.0 mg by IV (in the vein), once a month for 6 months
Study NCT00367003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: The deep brain stimulation system (consisting of a lead, extension wire, and implanted pulse generator) will be surgically implanted to stimulate the targeted area of the brain. Stimulation will be turned off for 4 weeks following implantation, then participants will use brain stimulation for 6 months. Participants will also take part in Behavioral Activation therapy during the 6 months of active stimulation. Participants will be followed for 10 years, or until the DBS device has been FDA approved, with adjustments made to the stimulator and medications as necessary.
Study NCT04907630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal Education
Description: educational intervention
Study NCT01332045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous saphenous nerve block
Description: Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
Study NCT01332045 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline boluses in nerve catheter
Description: A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
Study NCT02437006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: cycle ergometry
Study NCT01346254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: 50mg tablets once daily 20 min before breakfast for 3 months
Study NCT01346254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30mg tablets once daily 20 min before breakfast for 3 months
Study NCT01346254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-Style Modification
Description: All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
Study NCT01346254 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Life-Style Modification
Description: All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
Study NCT00508924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Study NCT00508924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin
Study NCT02728024 — intervention group
Intervention type: OTHER
Intervention: Missing items, Errors in Completion, Difficulties
Study NCT02474238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The sequential technique
Description: By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.
Study NCT02474238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The pure Nd:YAG laser technique
Description: By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
Study NCT00947453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: montelukast 10 mg once daily for 8 weeks
Study NCT03655717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol at physician determined doses of 10-80mg designed to produce intoxication.
Study NCT03655717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).
Study NCT03655717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo dronabinol
Description: Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)
Study NCT03655717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ethanol
Description: Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.
Study NCT04044092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative physical therapy
Description: Moist hot packs, TENS, Cervical Traction, Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
Study NCT04044092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELDOA stretching exercise
Description: Experimental group was given ELDOA stretching exercise protocol along with the moist hot packs, TENS, Cervical Traction, and Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
Study NCT02997917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study NCT02043405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss and exercise training intervention
Description: Combined weight loss and exercise training intervention
Study NCT02043405 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss Only Intervention
Description: Weight loss Only Intervention
Study NCT01561560 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
Study NCT01561560 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
Study NCT02997917 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT00447733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated mental health and substance use treatment
Description: Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
Study NCT00447733 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Non-standardized psychiatric outpatient treatment
Study NCT01087762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Description: 200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
Study NCT01087762 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 200 mg Q2W
Description: 200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
Study NCT01087762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q4W
Description: 400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
Study NCT01087762 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 400 mg Q4W
Description: 400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
Study NCT01087762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo to CZP injection.
Study NCT01087762 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to CZP injection.
Study NCT04815330 — intervention group
Intervention type: OTHER
Intervention: increment sweep gas flow
Description: If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.
Study NCT04815330 — intervention group
Intervention type: OTHER
Intervention: non-invasive ventilation
Description: In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved.
Study NCT01138826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine - reference
Description: 10 mg tablet, single dose, with water
Study NCT01138826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine ODT - test
Description: 10 mg orally disintegrating tablet (ODT), single dose, with water
Study NCT01138826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine ODT - test
Description: 10 mg orally disintegrating tablet (ODT), single dose, without water
Study NCT03939988 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Immediately after the installation of the separators, the subjects will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
Study NCT03939988 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo photobiomodulation
Description: In the placebo group, the same procedures will be made, but the laser will be turned off.
Study NCT03077529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-oligosacchride
Description: During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
Study NCT03077529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
Study NCT04233086 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational only
Description: No intervention, observational only
Study NCT00594646 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TRUVADA + Raltegravir
Description: TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
Study NCT03544398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: robot assisted gait training
Description: we use two types of robot assisted gait training and we will compare two groups.
Study NCT02320383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GA101 (Obinutuzumab)
Description: Induction~Cycle 1: d1 - 100 mg, (d1 or) d2 - 900 mg, d8+15 - 1000 mg i.v., q28d~Cycle 2 - 6: d1 - 1000 mg i.v., q28d~Maintenance~GA101 iv 1000 mg (flat dose): every 84 days
Study NCT02320383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Induction~Cycle 1: d3+4 (or d2+3) - 70 mg/m² i.v., q28d~Cycle 2 - 6: d2+3 - 70 mg/m i.v., q28d
Study NCT03544398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: robot assisted gait training
Description: we use two types of robot assisted gait training and we will compare two groups.
Study NCT03262727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration of specified dose on specified days
Study NCT03262727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Description: Oral Contraceptive
Study NCT04910659 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: P6, LI4 and LI 11 stimulation
Study NCT04910659 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: P6, LI4 and LI 11 stimulation
Study NCT03143478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M-MARK
Description: M-MARK will be used by therapists for assessment of the upper limb, and stroke participants will be asked to use M-MARK whilst performing individually tailored and prescribed exercises for a minimum of 5 days/week.~A set of tailored arm exercises using M-MARK (including targets for repetitive and functional activities) will be prescribed which the participant will be asked to practice independently at home for four weeks.~During the four weeks, the patient (with support from their carer as required) will be encouraged to don the M-Mark garment and log-on to the M-Mark computer tablet each day to carry out their programme of exercises. They will be asked to use M-Mark to repeat as many exercise sessions per day as prescribed to them by their research therapist.
Study NCT00583609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG3350
Description: PEG3350
Study NCT04450849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided tissue regeneration with using an absorbable collagen membrane associated with inorganic bovine bone associated.
Description: Dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) associated with inorganic bovine bone associated with collagen matrix (Bio-Oss® Collagen).
Study NCT04450849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: guided tissue regeneration with using an absorbable collagen membrane associated or not with inorganic bovine bone associated with collagen matrix.
Description: dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) alone.
Study NCT03746548 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Adhear
Description: Patients are wearing the Adhesive bone conduction hearing device (Adhear) for 2 weeks
Study NCT03052491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stem Cell 100+
Description: Open-Label 10-Component Dietary Supplement
Study NCT03228264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: teleSLT
Description: The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
Study NCT03228264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: teleSLT
Description: The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
Study NCT03746548 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Contact Mini (CM)
Description: Patients are wearing the Conventional bone conduction hearing device (Contact Mini) for 2 weeks
Study NCT02307214 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BaroReflex Sensitivity, endothelial function measurement
Description: no other
Study NCT03228264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: teleCT
Description: For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
Study NCT03228264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: teleCT
Description: For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
Study NCT00750997 — intervention group
Intervention type: DRUG
Intervention: hypertonic saline
Description: patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
Study NCT01258582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral HIV screening
Description: Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months
Study NCT01258582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fingerstick HIV screening
Description: Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
Study NCT03807518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Exercise Program
Description: Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing neo adjuvant therapy and for a six week period when deemed fit post surgery.
Study NCT01431170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besivance Treatment Group
Description: Subjects Receive Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.
Study NCT01431170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polytrim Treatment Group
Description: Subjects receive Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.
Study NCT01700426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.
Study NCT01700426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
Study NCT03119974 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tpo-RA discontinuation
Description: a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (> 2 months) complete response (platelets counts > 100 x 109/L) period on Tpo-RA treatment.
Study NCT01978210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wireless Moisture Pager (WMP)
Description: The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
Study NCT01978210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless Moisture Pager (WMP)
Description: The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
Study NCT00786422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.